Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Revvity is a life sciences and diagnostics company serving pharmaceutical, biotech, academic research, and clinical diagnostic markets with analytical instruments, reagents, and software. The company operates through two segments: Life Sciences (drug discovery tools, imaging systems, reagents) and Diagnostics (newborn screening, prenatal testing, infectious disease diagnostics), with significant exposure to biopharma R&D spending cycles and clinical laboratory volumes.
Revvity employs a razor-razorblade model, selling high-margin analytical instruments ($50K-$500K+ per unit) to pharmaceutical companies, biotech firms, and clinical labs, then generating recurring revenue from proprietary reagents, consumables, and multi-year service contracts. The Life Sciences segment benefits from long R&D cycles where customers make multi-year commitments to specific platforms. Diagnostics revenue is driven by test volumes in newborn screening (mandated by governments) and prenatal testing, with pricing power from regulatory barriers and installed base switching costs. Gross margins of 53% reflect mix of high-margin consumables (60-70% margins) offset by lower-margin instruments (40-50% margins).
Biopharma R&D spending trends and drug development pipeline activity (drives Life Sciences instrument and consumable demand)
Clinical diagnostic test volumes and reimbursement rates (affects Diagnostics segment recurring revenue)
New product launch cycles and instrument placement rates (particularly high-content imaging and detection platforms)
Geographic mix shifts between US (50-55% of revenue), Europe (25-30%), and China/Asia-Pacific (15-20%)
M&A activity and capital deployment decisions given $0.5B annual free cash flow generation
Technological disruption from next-generation sequencing and alternative analytical platforms that could obsolete current imaging and detection instrument franchises
Pricing pressure in diagnostics from payer reimbursement cuts and shift toward lower-cost point-of-care testing platforms
Regulatory risk in diagnostics segment from FDA oversight changes and international approval requirements for new assays
Intense competition from Thermo Fisher Scientific, Danaher (Beckman Coulter, Cepheid), and Agilent in life sciences tools with larger R&D budgets and broader product portfolios
Loss of market share in newborn screening to Quest Diagnostics and LabCorp as hospital labs consolidate
Chinese competitors (e.g., BGI, local instrument manufacturers) gaining share in Asia-Pacific markets with 40-50% lower pricing
Debt/Equity of 0.48 is manageable but limits M&A flexibility in consolidating life sciences tools industry
ROE of 3.2% and ROA of 2.0% are low for the sector, indicating capital efficiency challenges or recent acquisition integration costs
moderate - Life Sciences segment (60-65% of revenue) is tied to biopharma R&D budgets which are somewhat insulated from GDP cycles but sensitive to biotech funding availability and venture capital flows. Diagnostics segment is more defensive with recurring test volumes, though elective prenatal testing has discretionary elements. Overall revenue growth of 3.7% with declining margins suggests current headwinds from reduced biopharma spending and biotech funding constraints.
Rising rates negatively impact the business through two channels: (1) reduced biotech venture funding and IPO activity constrains Life Sciences customer capital equipment budgets, and (2) higher discount rates compress valuation multiples for growth-oriented life sciences tools companies. With Debt/Equity of 0.48 and $0.6B operating cash flow, financing costs are manageable but customer financing for large instrument purchases becomes more expensive. Current 17.9x EV/EBITDA suggests rate sensitivity in valuation.
Moderate exposure to biotech credit conditions. Early-stage biotech customers (20-30% of Life Sciences revenue) face funding constraints in tight credit environments, delaying instrument purchases and reducing consumable orders. Established pharma customers (40-50% of Life Sciences revenue) have minimal credit risk. Diagnostics segment has low credit exposure with hospital and government lab customers.
value - Trading at 3.9x Price/Sales and 17.9x EV/EBITDA with 4.6% FCF yield suggests value orientation, particularly given -14.1% one-year return and margin compression. Investors are likely focused on operational turnaround, margin recovery, and potential for multiple re-rating if biopharma spending recovers. Low ROE of 3.2% and negative earnings growth make this unattractive to growth investors currently.
moderate - Life sciences tools stocks typically have beta of 1.0-1.3 with volatility driven by quarterly earnings surprises, biopharma funding cycles, and M&A speculation. Recent 3-month return of 3.8% vs 6-month return of 6.6% but 1-year decline of -14.1% indicates elevated volatility during biotech funding downturn.
